PolyMedix Inc. is a biotechnology company focused on the development of novel drugs for the treatment of serious infectious diseases and acute cardiovascular disorders. The company today provided an update for its two lead clinical programs. These programs are the heptagonist PMX-60056 and the defensin-mimetic antibiotic PMX-30063.
PolyMedix anticipates conducting a Phase 1B/2 dose-ranging clinical trial for heptagonist PMX-60056 in the upcoming months. The trial is designed to evaluate the reversal of the low molecular weight heparin exoxoparin in healthy subjects. Data from this clinical trial will be used to establish a dose response correlation for enoxoparin and guide dosing for future trials. Results are expected before year-end.
In September 2010, PolyMedix initiated a Phase 2 clinical trial to evaluate the safety and efficacy of Antibiotic PMX-30063 in patients with acute bacterial skin and skin structure infections. This trial was to enroll 200 patients that have these infections due to methicillin-susceptible (MSSA) or methicillin-resistant (MRSA) Staph aureus.
Patients are randomized to receive one of three doses of PMX-30063 or the active control, daptomycin. Patients are assessed for response at both 48 and 72 hours and are then re-evaluated at days 10 to 15, and then at four week. Additional test sites for the drug in Europe are being set up with the full trial results to be released sometime in the first half of 2012.
For more information about PolyMedix, please visit the company’s website at www.polymedix.com
Let us hear your thoughts below: